Literature DB >> 147465

Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate.

B Ullman, M Lee, D W Martin, D V Santi.   

Abstract

Protein in vitro inhibition of thymidylate synthase (5,10-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1.45) by 5-fluoro-2'-deoxyuridylate requires 5,10-methylenetetrahydrofolate. The cytoxicity of 5-fluoro-2'-deoxyuridine towards cultured L1210 mouse leukemia cells is reduced when intracellular reduced folates are depleted, either by limiting the source in media or by inhibition of dihydrofolate reductase with methotrexate. Likewise, the intracellular amount of 5-fluoro-2'-deoxyuridylate covalently bound to thymidylate synthase in L1210 cells treated with 5-fluoro-2'-deoxyuridine is greatly diminished when cells are depleted of folate cofactors. The folate requirement for optimal growth of L1210 cells is lower than that required for maximal cytotoxicity of 5-fluoro-2'-deoxyuridine. These findings provide a biochemical rationale that may be useful in designing clinical protocols that use 5-fluorinated uracil analogs.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 147465      PMCID: PMC411383          DOI: 10.1073/pnas.75.2.980

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  STUDIES ON THE INHIBITION OF DIHYDROFOLATE REDUCTASE BY THE FOLATE ANTAGONISTS.

Authors:  J R BERTINO; B A BOOTH; A L BIEBER; A CASHMORE; A C SARTORELLI
Journal:  J Biol Chem       Date:  1964-02       Impact factor: 5.157

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

Review 3.  DEVELOPMENT, MAINTENANCE AND ASSAY OF DRUG RESISTANCE.

Authors:  G A FISCHER; A C SARTORELLI
Journal:  Methods Med Res       Date:  1964

4.  Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

Authors:  R J Langenbach; P V Danenberg; C Heidelberger
Journal:  Biochem Biophys Res Commun       Date:  1972-09-26       Impact factor: 3.575

Review 5.  Enzymology of cancer cells (first of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

6.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

7.  Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides.

Authors:  P V Danenberg; R J Langenbach; C Heidelberger
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

8.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

9.  5-Fluoro-2'-deoxyuridylate: covalent complex with thymidylate synthetase.

Authors:  D V Santi; C S McHenry
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

10.  Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate.

Authors:  H Sommer; D V Santi
Journal:  Biochem Biophys Res Commun       Date:  1974-04-08       Impact factor: 3.575

View more
  38 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

Authors:  P P Lee; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Folate and epigenetic mechanisms in neural tube development and defects.

Authors:  Sivan Vadakkadath Meethal; Kirk J Hogan; Chandra S Mayanil; Bermans J Iskandar
Journal:  Childs Nerv Syst       Date:  2013-09-07       Impact factor: 1.475

4.  Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity.

Authors:  J E Mortimer; I Anderson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

6.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

7.  Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.

Authors:  D J Fernandes; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.

Authors:  W Sadee; C G Wong
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

10.  5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.

Authors:  R Tausch-Treml; F Baumgart; D Ziessow; P Köpf-Maier
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.